Net Profit Margin
since 2005
Calculation
Biogen Inc., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income attributable to Biogen Inc.1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2021 | 14.17% | = | 100 | × | 1,556,100) | ÷ | 10,981,700) |
| Dec 31, 2020 | 29.76% | = | 100 | × | 4,000,600) | ÷ | 13,444,600) |
| Dec 31, 2019 | 40.96% | = | 100 | × | 5,888,500) | ÷ | 14,377,900) |
| Dec 31, 2018 | 32.93% | = | 100 | × | 4,430,700) | ÷ | 13,452,900) |
| Dec 31, 2017 | 20.69% | = | 100 | × | 2,539,100) | ÷ | 12,273,900) |
| Dec 31, 2016 | 32.34% | = | 100 | × | 3,702,800) | ÷ | 11,448,800) |
| Dec 31, 2015 | 32.95% | = | 100 | × | 3,547,000) | ÷ | 10,763,800) |
| Dec 31, 2014 | 30.25% | = | 100 | × | 2,934,784) | ÷ | 9,703,324) |
| Dec 31, 2013 | 26.87% | = | 100 | × | 1,862,341) | ÷ | 6,932,199) |
| Dec 31, 2012 | 25.02% | = | 100 | × | 1,380,033) | ÷ | 5,516,461) |
| Dec 31, 2011 | 24.45% | = | 100 | × | 1,234,428) | ÷ | 5,048,634) |
| Dec 31, 2010 | 21.31% | = | 100 | × | 1,005,273) | ÷ | 4,716,423) |
| Dec 31, 2009 | 22.16% | = | 100 | × | 970,132) | ÷ | 4,377,348) |
| Dec 31, 2008 | 19.11% | = | 100 | × | 783,167) | ÷ | 4,097,507) |
| Dec 31, 2007 | 20.12% | = | 100 | × | 638,172) | ÷ | 3,171,617) |
| Dec 31, 2006 | 8.11% | = | 100 | × | 217,511) | ÷ | 2,683,049) |
| Dec 31, 2005 | 6.63% | = | 100 | × | 160,711) | ÷ | 2,422,500) |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
- Net Income Attributable to Biogen Inc.
- The net income showed a consistent upward trend from 2005 through 2014, rising from approximately $161 million to around $3.5 billion. This growth was particularly pronounced between 2011 and 2014. After peaking in 2015 and 2016 at around $3.7 billion, net income experienced volatility with a significant dip in 2017 to $2.54 billion, followed by a strong recovery in 2018 and 2019, reaching the highest value of roughly $5.89 billion in 2019. However, this peak was followed by a noticeable decline in the subsequent years, dropping to $4.0 billion in 2020 and further to about $1.56 billion in 2021.
- Revenues
- Revenues exhibited steady growth from 2005 to 2014, increasing from approximately $2.42 billion to $10.76 billion. The increase accelerated significantly after 2011, with revenues surpassing $13 billion in 2018 and reaching their highest level of about $14.38 billion in 2019. Afterward, revenues declined to approximately $13.45 billion in 2020 and further to $10.98 billion in 2021, indicating a reversal in the previous growth trend during these two years.
- Net Profit Margin
- The net profit margin improved substantially over the decade, starting at 6.63% in 2005 and reaching over 30% from 2013 to 2016, peaking at 32.95% in 2014. Thereafter, it showed fluctuations, with a marked decrease to 20.69% in 2017, followed by a rebound to 32.93% in 2018 and its highest margin of 40.96% in 2019. The margin then declined noticeably in the last two years of the data, dropping to 29.76% in 2020 and further to 14.17% in 2021. This decline corresponds with the decreases observed in net income and revenues in the same period.
- Overall Insights
- The data reveals a period of strong financial growth from 2005 to 2014, characterized by increasing revenues, net income, and improving profit margins. The company reached its peak financial performance around 2019, followed by a marked downturn in 2020 and 2021. The declines in net income and revenues during these years, alongside the decreasing profit margins, suggest challenges impacting profitability and top-line growth, potentially warranting further investigation into underlying causes.
Comparison to Competitors
Biogen Inc., net profit margin, long-term trends, comparison to competitors
| Biogen Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2021 | 14.17% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | 29.76% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 31, 2019 | 40.96% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 31, 2018 | 32.93% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 20.69% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 32.34% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 32.95% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 30.25% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 26.87% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 25.02% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 24.45% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 21.31% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 22.16% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | 19.11% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 20.12% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 8.11% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 6.63% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Biogen Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Biogen Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2021 | 14.17% | 23.38% |
| Dec 31, 2020 | 29.76% | 14.07% |
| Dec 31, 2019 | 40.96% | 23.22% |
| Dec 31, 2018 | 32.93% | 19.82% |
| Dec 31, 2017 | 20.69% | 13.06% |
| Dec 31, 2016 | 32.34% | 20.78% |
| Dec 31, 2015 | 32.95% | 21.17% |
| Dec 31, 2014 | 30.25% | 21.24% |
| Dec 31, 2013 | 26.87% | 21.99% |
| Dec 31, 2012 | 25.02% | 18.53% |
| Dec 31, 2011 | 24.45% | 15.70% |
| Dec 31, 2010 | 21.31% | 15.16% |
| Dec 31, 2009 | 22.16% | 25.73% |
| Dec 31, 2008 | 19.11% | 18.17% |
| Dec 31, 2007 | 20.12% | 15.90% |
| Dec 31, 2006 | 8.11% | 22.24% |
| Dec 31, 2005 | 6.63% | 18.33% |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Biogen Inc., net profit margin, long-term trends, comparison to industry (health care)
| Biogen Inc. | Health Care | |
|---|---|---|
| Dec 31, 2021 | 14.17% | 15.24% |
| Dec 31, 2020 | 29.76% | 10.27% |
| Dec 31, 2019 | 40.96% | 14.56% |
| Dec 31, 2018 | 32.93% | 12.61% |
| Dec 31, 2017 | 20.69% | 9.26% |
| Dec 31, 2016 | 32.34% | 12.80% |
| Dec 31, 2015 | 32.95% | 13.94% |
| Dec 31, 2014 | 30.25% | 14.40% |
| Dec 31, 2013 | 26.87% | 15.04% |
| Dec 31, 2012 | 25.02% | 13.92% |
| Dec 31, 2011 | 24.45% | 12.06% |
| Dec 31, 2010 | 21.31% | 11.90% |
| Dec 31, 2009 | 22.16% | 17.77% |
| Dec 31, 2008 | 19.11% | 13.00% |
| Dec 31, 2007 | 20.12% | 12.52% |
| Dec 31, 2006 | 8.11% | 15.30% |
| Dec 31, 2005 | 6.63% | 14.61% |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).